Prior notification of a concentration

(Case M.8362 — Lonza Group/Capsugel)

(Text with EEA relevance)

(2017/C 96/07)

1. On 17 March 2017, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 [1] by which Lonza Group AG (Lonza, Switzerland) acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of the whole of Capsugel S.A. (Capsugel, Luxembourg) by way of a purchase of shares.

2. The business activities of the undertakings concerned are:

— Lonza: supply of services to the pharmaceutical, healthcare and life science industries, including contract development and manufacturing organisation services for biologics, fine chemicals, advanced intermediates and active pharmaceutical ingredients and manufacturing, development and commercialisation of active ingredients for use in consumer care, agriculture, water treatment, and coatings and composites,

— Capsugel: design, development and manufacture of a range of dosage forms for the biopharmaceutical and health and nutrition industries, including solid oral dosage delivery products such as hard gelatine, soft gelatine, liquid filled and alternative polymer capsules.

3. On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

4. The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by email to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference M.8362 — Lonza Group/Capsugel, to the following address:

European Commission
Directorate-General for Competition
Merger Registry
1049 Bruxelles/Brussel
BELGIQUE/BELGIË

[1] OJ L 24, 29.1.2004, p. 1 (the 'Merger Regulation').